GAZYVA, in combination with bendamustine followed by GAZYVA monotherapy, is
for the treatment of patients with follicular lymphoma who relapsed after OR are
refractory to a rituximab-containing regimen
Your FL patient
previously responded to a
rituximab-containing regimen
but has relapsed, and now
needs further treatment
It’s time to consider GAZYVA
in combination with bendamustine
Indication
GAZYVA ® (obinutuzumab), in combination with bendamustine followed by GAZYVA monotherapy, is indicated for the
treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen.
Boxed WARNINGS: HEPATITIS B VIRUS REACTIVATION AND PROGRESSIVE MULTIFOCAL
LEUKOENCEPHALOPATHY
• Hepatitis B Virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death,
can occur in patients receiving CD20-directed cytolytic antibodies, including GAZYVA. Screen all patients for
HBV infection before treatment initiation. Monitor HBV positive patients during and after treatment with
GAZYVA. Discontinue GAZYVA and concomitant medications in the event of HBV reactivation
• Progressive Multifocal Leukoencephalopathy (PML) including fatal PML, can occur in patients receiving GAZYVA
Please see the following pages for additional Important Safety Information and the brief summary of the full
Prescribing Information, including Boxed WARNINGS.